A blog about chemistry, drug development, science, and technology
It will be interesting to see how things develop with regards to new drug approvals and the FDA in 2008.
My guess is that for new drugs for which treatment already exists that the FDA will continue to demand evidence of not only of safety and effectiveness but also that is is an improvement over the currently available treatments. This seems to be shared by Fierce Biotech.
The FDA: Caught between a rock and a hard place - FierceBiotech
I can understand the FDA reacting to recent situations such as Vioxx but they do indeed seem to be sending a mixed message; emphasizing the need for speeding drugs to market but then seeming to have set a higher standard. THe FDA says therre jave been no policy changes but the fact that only 15 new drugs were approved in 2007 seems to indicate otherwise.
I just hope that we can have a open and honest discussion about risk management and acknowledge that all drugs have risk and many times that full impact of that will not be determined until after the drug has gone on the market.
Technorati Tags: drug approval, FDA
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 0.921 seconds